|Dr. Christian Martin Itin||Chairman & CEO||N/A||N/A||1964|
|Dr. Martin PulÃ©||Founder, Sr. VP, Chief Scientific Officer & Director||N/A||N/A||1972|
|Mr. Andrew J. Oakley||CFO & Sr. VP||N/A||N/A||1962|
|Mr. Christopher Vann||Sr. VP & COO||N/A||N/A||1965|
|Mr. David Brochu||Chief Technical Officer||N/A||N/A||1958|
|Mr. Matthias Alder||Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec.||N/A||N/A||1965|
|Dr. Muhammad Al-Hajj Ph.D.||Sr. VP of Translational Sciences||N/A||N/A||1971|
|Dr. Lucinda Crabtree Ph.D.||VP of IR & Corp. Communications||N/A||N/A||N/A|
|Mr. Vishal Mehta||VP & Head of Clinical Operations||N/A||N/A||N/A|
|Dr. Nushmia Khokhar||Sr. VP of Clinical Devel.||N/A||N/A||N/A|
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Autolus Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.